2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

NCT02916056 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
297
Enrollment
INDUSTRY
Sponsor class

Stopped Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.

Conditions

Interventions

Sponsor

vTv Therapeutics